申请人:Lilly Industries Limited
公开号:US04513005A1
公开(公告)日:1985-04-23
There are described pharmacologically active compounds, useful in the treatment of allergic/inflammatory disorders involving SRS-A as causal mediator and which, in free acid form, are of formula I, ##STR1## in which R.sub.1 is (i) an aliphatic, saturated or unsaturated hydrocarbyl radical of up to 20 carbon atoms, unsubstituted or substituted by at least one substituent selected from halogen, hydroxy, C.sub.3-6 alkoxy, C.sub.3-6 cycloalkyl, aryl or heteroaryl, the cycloalkyl, aryl or heteroaryl being unsubstituted or substituted by at least one substituent selected from hydroxy, halogen and alkyl, alkenyl or alkynyl of up to 10 carbon atoms, (ii) cycloalkyl of 3 to 8 carbon atoms unsubstituted or substituted by alkyl, alkenyl or alkynyl of up to 16 carbon atoms, or (iii) aryl or heteroaryl, unsubstituted or substituted by hydroxyl, C.sub.1-4 alkoxy, halogen or alkyl, alkenyl or alkynyl of up to 16 carbon atoms; and R.sub.2 is (i) alkyl, cycloalkyl or alkenyl of up to 10 carbon atoms, unsubstituted or substituted by one or more substituents selected from aryl, cycloalkyl, halogen, hydroxy, NHR.sub.3 and COX, where R.sub.3 is H, C.sub.1-4 alkyl, aryl or an amino acid residue or COX, and X is OH, C.sub.1-4 alkyl, NH.sub.2 or an amino acid residue, or (ii) aryl or heteroaryl, unsubstituted or substituted by one or more substituents selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-5 acyl, halogen, hydroxy, carboxy, nitro, trihalomethyl, phenyl, C.sub.1-4 acylamino and NHR.sub.4, where R.sub.4 is hydrogen or C.sub.1-4 alkyl; and Y is --S--, --SO-- or --SO.sub.2 --, with the proviso that when --YR.sub.2 is glutathionyl, cysteinyl or cysteinylglycinyl, then R.sub.1 is other than an unsubstituted alkatetraenyl or alkapentaenyl radical of 12 to 16 carbon atoms.
描述了在涉及SRS-A作为因果介质的过敏/炎症性疾病治疗中有用的药理活性化合物,这些化合物在游离酸形式下的化学式为I,其中R.sub.1是(i)具有多达20个碳原子的脂肪烃基、饱和或不饱和的烃基,未取代或被至少一种取代基取代,所述取代基选自卤素、羟基、C.sub.3-6烷氧基、C.sub.3-6环烷基、芳基或杂环芳基,所述环烷基、芳基或杂环芳基未取代或被至少一种取代基取代,所述取代基选自羟基、卤素和多达10个碳原子的烷基、烯基或炔基,(ii)具有3至8个碳原子的未取代或被多达16个碳原子的烷基、烯基或炔基取代的环烷基,或(iii)芳基或杂环芳基,未取代或被羟基、C.sub.1-4烷氧基、卤素或多达16个碳原子的烷基、烯基或炔基取代;R.sub.2是(i)多达10个碳原子的烷基、环烷基或烯基,未取代或被一个或多个取代基取代,所述取代基选自芳基、环烷基、卤素、羟基、NHR.sub.3和COX,其中R.sub.3为H、C.sub.1-4烷基、芳基或氨基酸残基或COX,X为OH、C.sub.1-4烷基、NH.sub.2或氨基酸残基,或(ii)芳基或杂环芳基,未取代或被一个或多个取代基取代,所述取代基选自C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.2-5酰基、卤素、羟基、羧基、硝基、三卤甲基、苯基、C.sub.1-4酰胺基和NHR.sub.4,其中R.sub.4为氢或C.sub.1-4烷基;Y为--S--、--SO--或--SO.sub.2--,但当--YR.sub.2为谱胱甘肽、半胱氨酸或半胱氨酰甘氨酸时,R.sub.1不是12至16个碳原子的未取代的α-四烯基或α-五烯基基团。